A Phase 3 randomized, double-masked study comparing theefficacy of EYP-1901 against aflibercept
Laufzeit: 01.01.2025 - 31.12.2025
imported
Kurzfassung
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
